Study of association between effect of first EGFR-TKI for EGFR-mutated non-small cell lung cancer and circulating tumor DNA detected with high sensitive analyses for EGFR mutation.

Study of association between effect of first EGFR-TKI for EGFR-mutated non-small cell lung cancer and circulating tumor DNA detected with high sensitive analyses for EGFR mutation. - Analysis of ctDNA and first EGFR-TKI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014092

Enrollment

Registered

2014-05-28

Start date

2014-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

From May 2014 to March 2016

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically or cytologically confirmed non-squamous, non-small cell lung cancer 2.Stage 3B, 4, or recurrent disease 3.EGFR mutation (exon 19 deletion,L858R) detected by PNA-LNA PCR clamp method 4.Untreated with EGFR-TKI 5.ECOG performance status (PS) 0 to 2 6.Adequate organ functions 7.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Received EGFR-TKI before this study 2.Interstitial pneumonitis or pulmonary fibrosis apparent on chest X-ray 3.Concomitant other malignancies

Design outcomes

Primary

Measure	Time frame
concordance rate of EGFR mutation between tumor and plasma	—

Countries

Japan

Contacts

Public ContactMakoto Maemondo

Miyagi Cancer Center Reapiratory Medicine

maemondo-ma6993@miyagi-pho.jp022-384-3151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026